Premium
History of preoperative therapy for pancreatic cancer and the MD Anderson experience
Author(s) -
Gaskill Cameron E.,
Maxwell Jessica,
Ikoma Naruhiko,
Kim Michael P.,
Tzeng ChingWei,
Lee Jeffrey E.,
Katz Matthew H. G.
Publication year - 2021
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.26394
Subject(s) - medicine , pancreatic cancer , perioperative , pancreatic ductal adenocarcinoma , chemotherapy , cancer , pancreatectomy , general surgery , adenocarcinoma , clinical trial , pancreaticoduodenectomy , oncology , surgery , pancreas
Systemic chemotherapy improves the survival of patients who undergo pancreatectomy, but whether chemotherapy should be delivered before or after surgery remains debated. At The University of Texas MD Anderson Cancer Center, localized pancreatic ductal adenocarcinoma (PDAC) has been preferentially treated with preoperative therapy—a practice supported by a robust history of institutional and national trials. In the following review, we discuss the historical use of perioperative therapy, our experience with it at MD Anderson Cancer Center and internationally, and the future of treatment and trials for PDAC.